News from the FDA/CDC

FDA: PrEP indication updated to include adolescents at risk of HIV infection


 


2.2 HIV-1 screening for individuals receiving Truvada for HIV-1 PrEP

Screen all patients for HIV-1 infection before initiating Truvada for HIV-1 PrEP and at least once every 3 months while taking Truvada

2.5 Recommended dosage for HIV-1 PrEP

The dosage of Truvada in HIV-1 uninfected adults and adolescents weighing at least 35 kg is one tablet (containing 200 mg of FTC and 300 mg of TDF) once daily taken orally with or without food.

Pages

Recommended Reading

Time to HIV rebound in infants off ART linked to birth health
MDedge Family Medicine
MDedge Daily News: Can androgen therapy improve male frailty?
MDedge Family Medicine
Medical marijuana’s ‘Catch-22’: Federal limits on research hinder patients’ relief
MDedge Family Medicine
Comorbidity occurs earlier and more commonly with HIV infection
MDedge Family Medicine
Antiretroviral choice for pregnant women with HIV does not appear to impact birth outcomes
MDedge Family Medicine
HIV infection linked to higher risk of non-melanoma skin cancer
MDedge Family Medicine
Most HIV patients need treatment for acute HCV
MDedge Family Medicine
Emotional regulation training lowers risk of adolescents having sex
MDedge Family Medicine
FDA seeks comments on pediatric HIV product development
MDedge Family Medicine
FDA approves epoetin alfa biosimilar to treat anemia
MDedge Family Medicine